{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T01:12:45Z","timestamp":1755825165907,"version":"3.44.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T00:00:00Z","timestamp":1755734400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T00:00:00Z","timestamp":1755734400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"DOI":"10.1186\/s12872-025-05093-w","type":"journal-article","created":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T05:21:02Z","timestamp":1755753662000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The prevalence and risk factors of hyperuricemia in patients with Newly-diagnosed coronary artery disease from 2017 to 2021"],"prefix":"10.1186","volume":"25","author":[{"given":"Shaofang","family":"Xian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiyu","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shanshan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaorong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiali","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,21]]},"reference":[{"issue":"1","key":"5093_CR1","doi-asserted-by":"publisher","first-page":"54","DOI":"10.15420\/ecr.2016:4:2","volume":"11","author":"ML Muiesan","year":"2016","unstructured":"Muiesan ML, Agabiti-Rosei C, Paini A, et al. Uric acid and cardiovascular disease: an update. Eur Cardiol Rev. 2016;11(1):54\u20139. https:\/\/doi.org\/10.15420\/ecr.2016:4:2.","journal-title":"Eur Cardiol Rev"},{"issue":"6","key":"5093_CR2","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1161\/01.hyp.36.6.1072","volume":"36","author":"P Verdecchia","year":"2000","unstructured":"Verdecchia P, Schillaci G, Reboldi G, et al. Relation between serum uric acid and risk of cardiovascular disease in essential hypertension. The PIUMA study. Hypertension. 2000;36(6):1072\u20138. https:\/\/doi.org\/10.1161\/01.hyp.36.6.1072.","journal-title":"Hypertension"},{"issue":"1","key":"5093_CR3","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1002\/acr.20344","volume":"63","author":"PC Grayson","year":"2011","unstructured":"Grayson PC, Kim SY, LaValley M, et al. Hyperuricemia and incident hypertension: a systematic review and meta-analysis. Arthritis Care Res. 2011;63(1):102\u201310. https:\/\/doi.org\/10.1002\/acr.20344.","journal-title":"Arthritis Care Res"},{"issue":"8","key":"5093_CR4","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1038\/hr.2014.75","volume":"37","author":"M Kuwabara","year":"2014","unstructured":"Kuwabara M, Niwa K, Nishi Y, et al. Relationship between serum uric acid levels and hypertension among Japanese individuals not treated for hyperuricemia and hypertension. Hypertens Res. 2014;37(8):785\u20139. https:\/\/doi.org\/10.1038\/hr.2014.75.","journal-title":"Hypertens Res"},{"issue":"5","key":"5093_CR5","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.jare.2017.04.008","volume":"8","author":"G Ragab","year":"2017","unstructured":"Ragab G, Elshahaly M, Bardin T, Gout. An old disease in new perspective - A review. J Adv Res. 2017;8(5):495\u2013511. https:\/\/doi.org\/10.1016\/j.jare.2017.04.008.","journal-title":"J Adv Res"},{"issue":"2","key":"5093_CR6","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1093\/aje\/kws002","volume":"176","author":"E Krishnan","year":"2012","unstructured":"Krishnan E, Pandya BJ, Chung L, et al. Hyperuricemia in young adults and risk of insulin resistance, prediabetes, and diabetes: a 15-year follow-up study. Am J Epidemiol. 2012;176(2):108\u201316. https:\/\/doi.org\/10.1093\/aje\/kws002.","journal-title":"Am J Epidemiol"},{"issue":"2","key":"5093_CR7","doi-asserted-by":"publisher","first-page":"105286","DOI":"10.1016\/j.jbspin.2021.105286","volume":"89","author":"T Bardin","year":"2022","unstructured":"Bardin T, Magnat E, Clerson P, et al. Epidemiology of gout and hyperuricemia in newly Caledonia. Joint Bone Spine. 2022;89(2):105286. https:\/\/doi.org\/10.1016\/j.jbspin.2021.105286.","journal-title":"Joint Bone Spine"},{"issue":"1","key":"5093_CR8","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s12872-021-02427-2","volume":"22","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Nie F-Q, Huang X-B, et al. High prevalence and low awareness of hyperuricemia in hypertensive patients among adults aged 50\u201379 years in Southwest China. BMC Cardiovasc Disord. 2022;22(1):2. https:\/\/doi.org\/10.1186\/s12872-021-02427-2.","journal-title":"BMC Cardiovasc Disord"},{"issue":"20","key":"5093_CR9","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.21037\/atm-21-5052","volume":"9","author":"S Pang","year":"2021","unstructured":"Pang S, Jiang Q, Sun P, et al. Hyperuricemia prevalence and its association with metabolic disorders: a multicenter retrospective real-world study in China. Ann Transl Med. 2021;9(20):1550. https:\/\/doi.org\/10.21037\/atm-21-5052.","journal-title":"Ann Transl Med"},{"issue":"1","key":"5093_CR10","doi-asserted-by":"publisher","first-page":"15683","DOI":"10.1038\/s41598-020-72780-3","volume":"10","author":"X-B Huang","year":"2020","unstructured":"Huang X-B, Zhang W-Q, Tang W-W, et al. Prevalence and associated factors of hyperuricemia among urban adults aged 35\u201379 years in Southwestern China: a community-based cross-sectional study. Sci Rep. 2020;10(1):15683. https:\/\/doi.org\/10.1038\/s41598-020-72780-3.","journal-title":"Sci Rep"},{"key":"5093_CR11","doi-asserted-by":"publisher","first-page":"791983","DOI":"10.3389\/fimmu.2021.791983","volume":"12","author":"M Zhang","year":"2021","unstructured":"Zhang M, Zhu X, Wu J, et al. Prevalence of hyperuricemia among Chinese adults: findings from two nationally representative Cross-Sectional surveys in 2015-16 and 2018-19. Front Immunol. 2021;12:791983. https:\/\/doi.org\/10.3389\/fimmu.2021.791983.","journal-title":"Front Immunol"},{"issue":"9","key":"5093_CR12","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.1007\/s10067-018-4130-2","volume":"37","author":"Y Kim","year":"2018","unstructured":"Kim Y, Kang J, Kim G-T. Prevalence of hyperuricemia and its associated factors in the general Korean population: an analysis of a population-based nationally representative sample. Clin Rheumatol. 2018;37(9):2529\u201338. https:\/\/doi.org\/10.1007\/s10067-018-4130-2.","journal-title":"Clin Rheumatol"},{"issue":"6","key":"5093_CR13","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1002\/art.40807","volume":"71","author":"M Chen-Xu","year":"2019","unstructured":"Chen-Xu M, Yokose C, Rai SK, et al. Contemporary prevalence of gout and hyperuricemia in the united States and decadal trends: the national health and nutrition examination survey, 2007\u20132016. Arthritis Rheumatol. 2019;71(6):991\u20139. https:\/\/doi.org\/10.1002\/art.40807.","journal-title":"Arthritis Rheumatol"},{"issue":"10","key":"5093_CR14","doi-asserted-by":"publisher","first-page":"3136","DOI":"10.1002\/art.30520","volume":"63","author":"Y Zhu","year":"2011","unstructured":"Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007\u20132008. Arthritis Rheum. 2011;63(10):3136\u201341. https:\/\/doi.org\/10.1002\/art.30520.","journal-title":"Arthritis Rheum"},{"key":"5093_CR15","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.2147\/DMSO.S252825","volume":"13","author":"KK Arersa","year":"2020","unstructured":"Arersa KK, Wondimnew T, Welde M, et al. Prevalence and determinants of hyperuricemia in type 2 diabetes mellitus patients attending Jimma medical center, Southwestern ethiopia, 2019. Diabetes Metab Syndr Obes. 2020;13:2059\u201367. https:\/\/doi.org\/10.2147\/DMSO.S252825.","journal-title":"Diabetes Metab Syndr Obes"},{"key":"5093_CR16","doi-asserted-by":"publisher","first-page":"6611","DOI":"10.2147\/IJGM.S376857","volume":"15","author":"M Abujbara","year":"2022","unstructured":"Abujbara M, Al Hourani HM, Al-Raoush RI, et al. Prevalence of hyperuricemia and associated factors among type 2 diabetic patients in Jordan. Int J Gen Med. 2022;6611\u20139. https:\/\/doi.org\/10.2147\/IJGM.S376857.","journal-title":"Int J Gen Med"},{"issue":"1","key":"5093_CR17","doi-asserted-by":"publisher","first-page":"4314","DOI":"10.1038\/s41598-018-22570-9","volume":"8","author":"P Song","year":"2018","unstructured":"Song P, Wang H, Xia W, et al. Prevalence and correlates of hyperuricemia in the middle-aged and older adults in China. Sci Rep. 2018;8(1):4314. https:\/\/doi.org\/10.1038\/s41598-018-22570-9.","journal-title":"Sci Rep"},{"issue":"8","key":"5093_CR18","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1177\/2047487314547652","volume":"22","author":"R Ferrari","year":"2015","unstructured":"Ferrari R, Ford I, Greenlaw N, et al. Geographical variations in the prevalence and management of cardiovascular risk factors in outpatients with CAD: data from the contemporary CLARIFY registry. Eur J Prev Cardiol. 2015;22(8):1056\u201365. https:\/\/doi.org\/10.1177\/2047487314547652.","journal-title":"Eur J Prev Cardiol"},{"issue":"9859","key":"5093_CR19","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1016\/S0140-6736(12)61728-0","volume":"380","author":"R Lozano","year":"2012","unstructured":"Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the global burden of disease study 2010. Lancet. 2012;380(9859):2095\u2013128. https:\/\/doi.org\/10.1016\/S0140-6736(12)61728-0.","journal-title":"Lancet"},{"issue":"7","key":"5093_CR20","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1002\/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S","volume":"15","author":"KG Alberti","year":"1998","unstructured":"Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998;15(7):539\u201353. https:\/\/doi.org\/10.1002\/(SICI)1096-9136(199807)15:7%3C;539::AID-DIA668%3E;3.0.CO;2-S.","journal-title":"Diabet Med"},{"issue":"2","key":"5093_CR21","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s40292-020-00368-z","volume":"27","author":"A Maloberti","year":"2020","unstructured":"Maloberti A, Giannattasio C, Bombelli M, et al. Hyperuricemia and risk of cardiovascular outcomes: the experience of the URRAH (uric acid right for heart health) project. High Blood Press Cardiovasc Prev. 2020;27(2):121\u20138. https:\/\/doi.org\/10.1007\/s40292-020-00368-z.","journal-title":"High Blood Press Cardiovasc Prev"},{"issue":"9842","key":"5093_CR22","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1016\/S0140-6736(12)61085-X","volume":"380","author":"GA Giovino","year":"2012","unstructured":"Giovino GA, Mirza SA, Samet JM, et al. Tobacco use in 3 billion individuals from 16 countries: an analysis of nationally representative cross-sectional household surveys. Lancet. 2012;380(9842):668\u201379. https:\/\/doi.org\/10.1016\/S0140-6736(12)61085-X.","journal-title":"Lancet"},{"issue":"2","key":"5093_CR23","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.atherosclerosis.2008.03.001","volume":"201","author":"Y Bao","year":"2008","unstructured":"Bao Y, Lu J, Wang C, et al. Optimal waist circumference cutoffs for abdominal obesity in Chinese. Atherosclerosis. 2008;201(2):378\u201384. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2008.03.001.","journal-title":"Atherosclerosis"},{"key":"5093_CR24","doi-asserted-by":"publisher","first-page":"655","DOI":"10.2147\/RMHP.S293913","volume":"14","author":"W Liu","year":"2021","unstructured":"Liu W, Liu W, Wang S, et al. Prevalence and risk factors associated with hyperuricemia in the Pearl River Delta, Guangdong province, China. Risk Manag Healthc Policy. 2021;655\u201363. https:\/\/doi.org\/10.2147\/RMHP.S293913.","journal-title":"Risk Manag Healthc Policy"},{"issue":"5","key":"5093_CR25","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1136\/annrheumdis-2011-201254","volume":"72","author":"G Trifir\u00f2","year":"2013","unstructured":"Trifir\u00f2 G, Morabito P, Cavagna L, et al. Epidemiology of gout and hyperuricaemia in Italy during the years 2005\u20132009: a nationwide population-based study. Ann Rheum Dis. 2013;72(5):694\u2013700. https:\/\/doi.org\/10.1136\/annrheumdis-2011-201254.","journal-title":"Ann Rheum Dis"},{"issue":"19","key":"5093_CR26","doi-asserted-by":"publisher","first-page":"4095","DOI":"10.3390\/nu14194095","volume":"14","author":"W Piao","year":"2022","unstructured":"Piao W, Zhao L, Yang Y, et al. The prevalence of hyperuricemia and its correlates among adults in China: results from CNHS 2015\u20132017. Nutrients. 2022;14(19):4095. https:\/\/doi.org\/10.3390\/nu14194095.","journal-title":"Nutrients"},{"issue":"4","key":"5093_CR27","doi-asserted-by":"publisher","first-page":"590","DOI":"10.6133\/apjcn.2013.22.4.16","volume":"22","author":"J Wang","year":"2013","unstructured":"Wang J, Chen R-P, Lei L, et al. Prevalence and determinants of hyperuricemia in type 2 diabetes mellitus patients with central obesity in Guangdong Province in China. Asia Pac J Clin Nutr. 2013;22(4):590\u20138. https:\/\/doi.org\/10.6133\/apjcn.2013.22.4.16.","journal-title":"Asia Pac J Clin Nutr"},{"key":"5093_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2024.132527","volume":"417","author":"A Maloberti","year":"2024","unstructured":"Maloberti A, Tognola C, Garofani I, et al. Uric acid and metabolic syndrome: importance of hyperuricemia cut-off. Int J Cardiol. 2024;417: 132527. https:\/\/doi.org\/10.1016\/j.ijcard.2024.132527.","journal-title":"Int J Cardiol"},{"issue":"5","key":"5093_CR29","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s40292-024-00665-x","volume":"31","author":"M Fortuna","year":"2024","unstructured":"Fortuna M, Tognola C, Algeri M, et al. Hyperuricemia in cardiac rehabilitation patients: prevalence and association with functional improvement and left ventricular ejection fraction. High Blood Press Cardiovasc Prev. 2024;31(5):461\u201371. https:\/\/doi.org\/10.1007\/s40292-024-00665-x.","journal-title":"High Blood Press Cardiovasc Prev"},{"issue":"1","key":"5093_CR30","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.numecd.2020.08.015","volume":"31","author":"A Maloberti","year":"2021","unstructured":"Maloberti A, Qualliu E, Occhi L, et al. Hyperuricemia prevalence in healthy subjects and its relationship with cardiovascular target organ damage. Nutr Metab Cardiovasc Dis. 2021;31(1):178\u201385. https:\/\/doi.org\/10.1016\/j.numecd.2020.08.015.","journal-title":"Nutr Metab Cardiovasc Dis"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-025-05093-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12872-025-05093-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-025-05093-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T05:21:02Z","timestamp":1755753662000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccardiovascdisord.biomedcentral.com\/articles\/10.1186\/s12872-025-05093-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,21]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["5093"],"URL":"https:\/\/doi.org\/10.1186\/s12872-025-05093-w","relation":{},"ISSN":["1471-2261"],"issn-type":[{"type":"electronic","value":"1471-2261"}],"subject":[],"published":{"date-parts":[[2025,8,21]]},"assertion":[{"value":"5 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the First Affiliated Hospital of Jinan University Ethics Committee (Ethical Approval Number: 20190812-033). Written informed consent was obtained from patients enrolled between 2017 and 2019, but patients enrolled from 2020 to 2021 were only verbally informed consent about the study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"620"}}